New CAR-T therapy takes aim at tough lymphoma cancers
NCT ID NCT07539688
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called CY-219 CAR-T cells in 18 people whose B-cell lymphoma has come back or stopped responding to standard care. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The main goals are to see if the treatment is safe and to measure how well it shrinks tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Light-Based device spot dangerous infection risk without a blood draw?